Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosisColm Elliott, Douglas L. Arnold, Shibeshih Belachew et al.|Brain|2019Cited by 217
Five years of ocrelizumab in relapsing multiple sclerosisStephen L. Hauser, Xavier Montalbán, Bruno Brochet et al.|Neurology|2020Cited by 159